Duchenne Muscular Dystrophy Drugs Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Molecular-based Therapies
1.2.3 Steroid Therapy
1.2.4 Other
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Perspective (2017-2028)
2.2 Duchenne Muscular Dystrophy Drugs Growth Trends by Region
2.2.1 Duchenne Muscular Dystrophy Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Duchenne Muscular Dystrophy Drugs Historic Market Size by Region (2017-2022)
2.2.3 Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028)
2.3 Duchenne Muscular Dystrophy Drugs Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Drugs Industry Trends
2.3.2 Duchenne Muscular Dystrophy Drugs Market Drivers
2.3.3 Duchenne Muscular Dystrophy Drugs Market Challenges
2.3.4 Duchenne Muscular Dystrophy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Drugs Players by Revenue (2017-2022)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue
3.4 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2021
3.5 Duchenne Muscular Dystrophy Drugs Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Type (2017-2022)
4.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Drugs Historic Market Size by Application (2017-2022)
5.2 Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
6.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type
6.2.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022)
6.2.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028)
6.2.3 North America Duchenne Muscular Dystrophy Drugs Market Share by Type (2017-2028)
6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Application
6.3.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022)
6.3.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028)
6.3.3 North America Duchenne Muscular Dystrophy Drugs Market Share by Application (2017-2028)
6.4 North America Duchenne Muscular Dystrophy Drugs Market Size by Country
6.4.1 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
6.4.2 North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type
7.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022)
7.2.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028)
7.2.3 Europe Duchenne Muscular Dystrophy Drugs Market Share by Type (2017-2028)
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application
7.3.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022)
7.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028)
7.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Share by Application (2017-2028)
7.4 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country
7.4.1 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
7.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type
8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region
8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
9.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type
9.2.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Duchenne Muscular Dystrophy Drugs Market Share by Type (2017-2028)
9.3 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application
9.3.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Duchenne Muscular Dystrophy Drugs Market Share by Application (2017-2028)
9.4 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country
9.4.1 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size (2017-2028)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type
10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country
10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Introduction
11.1.4 Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.1.5 Biogen Recent Developments
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Introduction
11.2.4 Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.2.5 Roche Recent Developments
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Details
11.3.2 Daiichi Sankyo Business Overview
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Introduction
11.3.4 Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.3.5 Daiichi Sankyo Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Introduction
11.4.4 Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.4.5 Pfizer Recent Developments
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Details
11.5.2 Cumberland Pharmaceuticals Business Overview
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.5.4 Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.5.5 Cumberland Pharmaceuticals Recent Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Details
11.6.2 Santhera Pharmaceuticals Business Overview
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.6.5 Santhera Pharmaceuticals Recent Developments
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Details
11.7.2 Taiho Pharmaceutical Business Overview
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Introduction
11.7.4 Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.7.5 Taiho Pharmaceutical Recent Developments
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Details
11.8.2 Teijin Pharma Business Overview
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Introduction
11.8.4 Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.8.5 Teijin Pharma Recent Developments
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Details
11.9.2 Akashi Therapeutics Business Overview
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.9.4 Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.9.5 Akashi Therapeutics Recent Developments
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Details
11.10.2 Sarepta Therapeutics Business Overview
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Introduction
11.10.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.10.5 Sarepta Therapeutics Recent Developments
11.11 BioMarin
11.11.1 BioMarin Company Details
11.11.2 BioMarin Business Overview
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Introduction
11.11.4 BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.11.5 BioMarin Recent Developments
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Details
11.12.2 Fibrogen Inc Business Overview
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Introduction
11.12.4 Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.12.5 Fibrogen Inc Recent Developments
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Details
11.13.2 Nobelpharma Co. Ltd Business Overview
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Introduction
11.13.4 Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.13.5 Nobelpharma Co. Ltd Recent Developments
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Details
11.14.2 Eloxx Pharmaceuticals Business Overview
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Introduction
11.14.4 Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
11.14.5 Eloxx Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Molecular-based Therapies
Table 3. Key Players of Steroid Therapy
Table 4. Key Players of Other
Table 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2017-2022)
Table 9. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Share by Region (2023-2028)
Table 11. Duchenne Muscular Dystrophy Drugs Market Trends
Table 12. Duchenne Muscular Dystrophy Drugs Market Drivers
Table 13. Duchenne Muscular Dystrophy Drugs Market Challenges
Table 14. Duchenne Muscular Dystrophy Drugs Market Restraints
Table 15. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Players (2017-2022)
Table 17. Global Top Duchenne Muscular Dystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Drugs Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Duchenne Muscular Dystrophy Drugs Product Solution and Service
Table 22. Date of Enter into Duchenne Muscular Dystrophy Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2017-2022)
Table 26. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2023-2028)
Table 28. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Application (2017-2022)
Table 30. Global Duchenne Muscular Dystrophy Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Application (2023-2028)
Table 32. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 62. Biogen Company Details
Table 63. Biogen Business Overview
Table 64. Biogen Duchenne Muscular Dystrophy Drugs Product
Table 65. Biogen Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 66. Biogen Recent Developments
Table 67. Roche Company Details
Table 68. Roche Business Overview
Table 69. Roche Duchenne Muscular Dystrophy Drugs Product
Table 70. Roche Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 71. Roche Recent Developments
Table 72. Daiichi Sankyo Company Details
Table 73. Daiichi Sankyo Business Overview
Table 74. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product
Table 75. Daiichi Sankyo Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 76. Daiichi Sankyo Recent Developments
Table 77. Pfizer Company Details
Table 78. Pfizer Business Overview
Table 79. Pfizer Duchenne Muscular Dystrophy Drugs Product
Table 80. Pfizer Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 81. Pfizer Recent Developments
Table 82. Cumberland Pharmaceuticals Company Details
Table 83. Cumberland Pharmaceuticals Business Overview
Table 84. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 85. Cumberland Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 86. Cumberland Pharmaceuticals Recent Developments
Table 87. Santhera Pharmaceuticals Company Details
Table 88. Santhera Pharmaceuticals Business Overview
Table 89. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 90. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 91. Santhera Pharmaceuticals Recent Developments
Table 92. Taiho Pharmaceutical Company Details
Table 93. Taiho Pharmaceutical Business Overview
Table 94. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product
Table 95. Taiho Pharmaceutical Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 96. Taiho Pharmaceutical Recent Developments
Table 97. Teijin Pharma Company Details
Table 98. Teijin Pharma Business Overview
Table 99. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product
Table 100. Teijin Pharma Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 101. Teijin Pharma Recent Developments
Table 102. Akashi Therapeutics Company Details
Table 103. Akashi Therapeutics Business Overview
Table 104. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 105. Akashi Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 106. Akashi Therapeutics Recent Developments
Table 107. Sarepta Therapeutics Company Details
Table 108. Sarepta Therapeutics Business Overview
Table 109. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product
Table 110. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 111. Sarepta Therapeutics Recent Developments
Table 112. BioMarin Company Details
Table 113. BioMarin Business Overview
Table 114. BioMarin Duchenne Muscular Dystrophy Drugs Product
Table 115. BioMarin Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 116. BioMarin Recent Developments
Table 117. Fibrogen Inc Company Details
Table 118. Fibrogen Inc Business Overview
Table 119. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product
Table 120. Fibrogen Inc Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 121. Fibrogen Inc Recent Developments
Table 122. Nobelpharma Co. Ltd Company Details
Table 123. Nobelpharma Co. Ltd Business Overview
Table 124. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product
Table 125. Nobelpharma Co. Ltd Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 126. Nobelpharma Co. Ltd Recent Developments
Table 127. Eloxx Pharmaceuticals Company Details
Table 128. Eloxx Pharmaceuticals Business Overview
Table 129. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product
Table 130. Eloxx Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Drugs Business (2017-2022) & (US$ Million)
Table 131. Eloxx Pharmaceuticals Recent Developments
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2021 VS 2028
Figure 2. Molecular-based Therapies Features
Figure 3. Steroid Therapy Features
Figure 4. Other Features
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2021 VS 2028
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 10. Global Duchenne Muscular Dystrophy Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 11. Global Duchenne Muscular Dystrophy Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Duchenne Muscular Dystrophy Drugs Market Share by Region: 2021 VS 2028
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market Share by Players in 2021
Figure 14. Global Top Duchenne Muscular Dystrophy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Drugs as of 2021)
Figure 15. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Drugs Revenue in 2021
Figure 16. North America Duchenne Muscular Dystrophy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 17. North America Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2017-2028)
Figure 18. North America Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2017-2028)
Figure 19. North America Duchenne Muscular Dystrophy Drugs Market Size Share by Country (2017-2028)
Figure 20. United States Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Canada Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Europe Duchenne Muscular Dystrophy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 23. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2017-2028)
Figure 24. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2017-2028)
Figure 25. Europe Duchenne Muscular Dystrophy Drugs Market Size Share by Country (2017-2028)
Figure 26. Germany Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. France Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. U.K. Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Italy Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Russia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Nordic Countries Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 33. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2017-2028)
Figure 34. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2017-2028)
Figure 35. Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Share by Region (2017-2028)
Figure 36. China Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 42. Latin America Duchenne Muscular Dystrophy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 43. Latin America Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2017-2028)
Figure 44. Latin America Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2017-2028)
Figure 45. Latin America Duchenne Muscular Dystrophy Drugs Market Size Share by Country (2017-2028)
Figure 46. Mexico Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2017-2028)
Figure 50. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2017-2028)
Figure 51. Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Share by Country (2017-2028)
Figure 52. Turkey Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. UAE Duchenne Muscular Dystrophy Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Biogen Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 56. Roche Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 57. Daiichi Sankyo Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 58. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 59. Cumberland Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 60. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 61. Taiho Pharmaceutical Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 62. Teijin Pharma Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 63. Akashi Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 64. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 65. BioMarin Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 66. Fibrogen Inc Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 67. Nobelpharma Co. Ltd Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 68. Eloxx Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Drugs Business (2017-2022)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Industry Market Size
